Moderna said on Monday that its combination vaccine that targets COVID-19 and the flu was more effective than their current separate vaccines for both viruses, according to new late-stage clinical trial data.
The pharmaceutical giant is the first company to release Phase 3 clinical trial data on a combination flu-COVID vaccine, leading the industry over rivals such as Novavax and Pfizer.
Real journalism.Trusted by millions.
Unlimited access to in-depth reporting, expert analysis, and the stories that shape our country.
Subscribe Now
Already a member? Log in
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.